- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill restricts mifepristone (abortion pill) prescriptions by requiring in-person visits and limiting out-of-state telehealth providers. It strengthens state-level protections against remote abortion access.
Law Today
Currently, REMS-certified providers may prescribe mifepristone (an abortion-inducing drug) through remote consultations and mail delivery under FDA regulations that permit dispensing without a required in-person visit.
If Passed
This bill would require that mifepristone be prescribed only after an in-person visit and only by a provider with a medical license in the patient's state of residence, effectively eliminating mail-order abortion and out-of-state telemedicine abortion services.
AI-generated from the bill text — verify against the official text.
Should I support this?
- Strongly Oppose
- Likely Oppose
- Neutral
- This billLikely Support
- Strongly Support
Likely Support
This bill aligns with Christian pro-life values by restricting access to medication abortion and requiring in-person medical oversight and state licensure, preventing circumvention of state protections for unborn life and parental authority. Christian parents who hold pro-life convictions would generally view stronger limits on abortion access as affirming the sanctity of life.
AI assessment using F3’s editorial criteria — faith, family, and freedom. This is F3’s policy judgment; verify the provisions in the official bill text.
Likely supporters & opponents
Likely support
- pro-life advocacy organizations — Requiring in-person visits and state licensure creates regulatory oversight and adds protective measures to reduce what they view as unsafe or irresponsible chemical abortion.
- religious-liberty and pro-family advocacy organizations — Restricting remote abortion access aligns with values protecting unborn life and parental notification rights, and prevents circumvention of state abortion laws.
- state medical boards and traditional medical associations — Requiring in-state medical licensure and in-person evaluation upholds medical licensing standards and physician accountability within state jurisdiction.
Likely opposition
- reproductive-rights and civil-liberties organizations — The requirement restricts access to FDA-approved medication and infringes on patients' constitutional rights and interstate travel freedoms, particularly for women in pro-life states.
- medical professionals and physician associations — Requiring in-person visits contradicts FDA safety data showing medication abortion is safe via telehealth and adds unnecessary barriers to evidence-based medical care.
- abortion-access advocacy organizations — The bill effectively nullifies abortion access in states with strict bans by blocking out-of-state and mail-based options, disproportionately harming low-income and rural women.
AI-inferred typical positions based on the bill’s substance — general stakeholder categories, not confirmed endorsements.
Official summary
To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
Sponsors
- Sheri Biggs (R)
- Russell Fry (R)
- Ralph Norman (R)
- Harriet Hageman (R)
- Claudia Tenney (R)
- Greg Steube (R)
- Mike Bost (R)
- William Timmons (R)
- Roger Williams (R)
- Michelle Fischbach (R)
- Andy Harris (R)
- Pete Stauber (R)
Status timeline
- 2026-06-24Referred to the House Committee on Energy and Commerce.H
- 2026-06-24Introduced in HouseH
H = House · S = Senate · A = Assembly